Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 311, Issue -, Pages 71-78Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2017.08.005
Keywords
ONX-0914; Immunoproteasome; Experimental autoimmune myasthenia gravis; Humoral immunity
Categories
Funding
- National Natural Science Foundation of China [81471222]
- Taishan Scholars Construction Engineering of Shandong Province [ts20130914]
Ask authors/readers for more resources
Accumulating evidence shows that the immunoproteasome participates in the immune response, beyond its initial role in the protein degradation. Here, we tested the effects of the selective immunoproteasome inhibitor, ONX-0914, on experimental autoimmune myasthenia gravis (EAMG). We found that ONX-0914 ameliorated the severity of ongoing EAMG by reducing the autoantibody affinity, accompanied with decreased Tfh cells and antigen presenting cells. Also it reduced the percentage of Th17 cells and inhibited the secretion of IL-17. Our data indicated ONX-0914 may bring benefit for MG therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available